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Abstract
Background: A typical pathological feature of Alzheimer’s disease (AD) is the appearance in the brain of senile plaques
made up of b-amyloid (Ab) and neurofibrillary tangles. AD is also associated with an abnormal accumulation of some metal
ions, and we have recently shown that one of these, aluminum (Al), plays a relevant role in affecting Ab aggregation and
neurotoxicity.
Methodology: In this study, employing a microarray analysis of 35,129 genes, we investigated the effects induced by the
exposure to the Ab1–42-Al (Ab-Al) complex on the gene expression profile of the neuronal-like cell line, SH-SY5Y.
Principal Findings: The microarray assay indicated that, compared to Ab or Al alone, exposure to Ab-Al complex produced
selective changes in gene expression. Some of the genes selectively over or underexpressed are directly related to AD. A
further evaluation performed with Ingenuity Pathway analysis revealed that these genes are nodes of networks and
pathways that are involved in the modulation of Ca2+ homeostasis as well as in the regulation of glutamatergic transmission
and synaptic plasticity.
Conclusions and Significance: Ab-Al appears to be largely involved in the molecular machinery that regulates neuronal as
well as synaptic dysfunction and loss. Ab-Al seems critical in modulating key AD-related pathways such as glutamatergic
transmission, Ca2+ homeostasis, oxidative stress, inflammation, and neuronal apoptosis.
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Introduction
The abnormal deposition and aggregation of b-amyloid (Ab) in
senile plaques are hallmarks features of the Alzheimer’s disease
(AD) brain. Senile plaques are made up of aggregates of misfolded
Ab that are associated with high concentrations of several
endogenous or exogenous metal ions (Fe, Zn, Cu, and Al), but
they also contain cell elements migrating from the immuno-
response system [1,2]. Metal ions have been indicated as
important co-risk factors in several neurodegenerative disorders
[3,4] and, in the context of AD, recent studies have shown that
they are key in accelerating Ab oligomerization as well as
modifying the neurotoxic properties of the amyloid peptide
[5,6,7]. In that respect, we have recently shown that Fe, Zn, Cu,
and Al can each specifically affect the pathogenic actions of Ab
[8]. We have also reported that, compared to other Ab-metal
complexes (Ab-Fe, Ab-Zn, Ab-Cu), Ab-Al is unique in promoting
a specific form of Ab oligomerization that has marked neurotoxic
effects [8].
In this study, we have continued to explore the molecular
determinants involved in the toxicity induced by the Ab1–42-Al (Ab-
Al) complex. To that aim, we investigated changes in the gene
expression profile of neuronal cell lines, the SH-SY5Y, exposed to
either Ab, the Ab-Al complex or Al alone, against untreated cultures.
SH-SY5Y cells were chosen because as cell line they offer the
advantage of being a homogenous population that does not show the
subtype heterogeneity present in primary neuronal cultures, a
confounding factor that would make the results hard to interpreter.
Cultures were exposed to Ab, the Ab-Al complex or Al alone
and investigated for gene profile changes by microarray analysis, a
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technique that provides a powerful way to identify novel genes
involved in physiopathological signaling cascades. This analytical
approach has been found to be particularly productive in multi-
factorial disorders such as AD [9,10,11]. At first, we employed an
analysis of the total genome (35,129 transcripts) of SH-SY5Y
exposed to Ab, the Ab-Al complex or Al under strictly comparable
experimental conditions. After this large set of data was collected,
we investigated the role and function of genes that were found
selectively changed by the exposure to Ab-Al. By using the
Ingenuity Pathway Analysis (IPA) we then studied key biological
functions, networks, and pathways related to these genes. Finally,
we analyzed the genes changed by the Ab-Al complex that are
known to be involved in AD and present in the alzgene database
(http://www.alzgene.org). Results from this study provide an
advanced database that may help in deciphering the genetics of
AD and serves as a potential model to promote a better
understanding of the pathogenic interplay between Al accumula-
tion, Ab aggregation, and its neurotoxicity.
Results
Gene expression profile of SH-SY5Y cells treated with the
Ab-Al complex
To gain insights on the global changes in gene expression
produced by the exposure to the Ab-Al complex in human SH-
SY5Y neuroblastoma cells, microarray analysis was performed
and results selectively compared with gene expression of cultures
exposed to Ab or Al. Cells were incubated with Ab or the Ab-Al
complex for 24 h. In control experiments, the same cell treatment
was also performed in the presence of Al at a concentration 10-fold
higher than what used for the peptide exposure. Other studies
have already shown that Al is a potent modulator of gene
expression at both high and low concentrations [12][13,14]. After
evaluating a total of ten experiments, transcripts expression was
analyzed and genes differentially expressed by the Ab-Al complex
were selected. A gene was considered to be differentially expressed
when showing an absolute value of log-ratio higher or equal to 0.5,
an index that translates to a fold-change of 1.4 in transcript
quantity. On a total of 28676 transcripts, the exposure to the Ab-
Al complex promoted the selective overexpression of 1535 genes
while 1815 were downexpressed (Tables S1, S2). Among these
genes we found a gene subset that is directly related to AD. When
we matched our results with the 584 AD-related genes present in
the alzgene database (http://www.alzgene.org), we found that 29
of those were upregulated and 23 downregulated (see Tables 1, 2).
TaqMan real time quantitative PCR: Validation of the
microarray data
To validate the microarray results, qRT-PCR analysis was
performed on SH-SY5Y cells exposed to the same experimental
conditions used for the microarray assay. In the case of the Ab-Al
complex exposure, genes investigated by quantitative PCR were
found to be the same changed in the microarray assay (i.e.:
APLP1, APLP2, MAPT; Figures S1 and S2).
Biological functions associated with genes selectively
changed by the exposure to the Ab-Al complex
After the identification of genes selectively changed by the exposure to
the Ab-Al complex, we employed Ingenuity Pathway Analysis (IPA) to
further investigate key biological functions linked to these genes. In the
case of the upregulated gene dataset (n=1535), we found that the main
central nervous system (CNS) functions involved were: amino acid
metabolism, DNA replication recombination and repair, lipid metab-
olism, cellular function and maintenance, cell death, cell morphology,
cell signaling, nervous system development and function, cellular
compromise, neurological disease, as well as RNA damage and repair
(Figure 1A, Table 3). IPA analysis of the downregulated genes (n=1815)
showed functions in the categories of cell-to-cell signaling and interaction,
inflammatory response, cellular development, molecular transport, cell
death, lipid metabolism, neurological disease, free radical scavenging,
cellular assembly and organization, post-translational modification as
well as DNA replication recombination and repair (Figure 1B, Table 4).
Networks associated with genes selectively changed by
the exposure to the Ab-Al complex
IPA predicts functional networks based on known protein-protein
and functional interactions. IPA infers and ranks networks by a score,
expressed as a numerical value, which is a probabilistic fit between the
amount of focus genes that are potentially eligible for a network
composition and present on a given gene list, the size of the network,
as well as all the molecules present in the Ingenuity Knowledge Base
that can be part of such a network. We therefore employed IPA to
study how the genes selectively changed in their expression by the Ab-
Al exposure were interacting in specific networks.
Networks associated with upregulated genes. Analysis of
the upregulated genes indicated 25 networks with a score ranging
from 46 to 13, the four top networks generated by IPA are
provided in Fig. 2 and Tables S3, S4, S5, S6.
The first network (Figure 2A, Table S3) involves nodes of genes
that participate in the inflammatory response (TGFB1) as well as
in synaptic functioning (ARRB1 and APLP1).
The second network (Figure 2B, Table S4) involves nodes of genes
that play an important role in oxidative stress (NOS), endocytosis
(clathrin), inflammatory response (AP1), and apoptosis (JUN).
The third network (Figure 2C and Table S5) involves nodes of
genes that serve a role in AbPP processing (Furin), synapse
development (MEF2), neuroprotection (NR41), insulin metabolism
(IDE), and histones deacetylation (HDAC9).
The fourth network (Figure 2D and Table S6) is built on nodes
of genes that participate in the cleavage of fatty acids (PLA2), in
calcium signalling (calmodulin) as well as in glutamatergic
neurotransmission (GRIN1, GRIN2c).
Networks associated with downregulated genes. Analysis
of the downregulated genes showed 25 networks with a score
ranging from 39 to 14. The four top networks are provided in
Figure 3 and Tables S7, S8, S9, S10.
The first network (Fig. 3A and Table S7) is centered on nodes of
genes involved in the morphological and functional integrity of
synapses (Homer, Homer I), preservation of cholinergic activity
(ESR1), and gene expression (EP300).The second network
(Figure 3B and Table S8) shows nodes involved in apoptosis
(CDH1) and cell motility (G-actin).
The third highest ranked network (Figure 3C and Table S9) is
focused on down regulated genes that are involved in biological
functions related to aminoacid metabolism and post translational
modification. The main network nodes are represented by Protein
kinase C (PKC) and SHANK2.
The fourth down regulated network (Figure 3D; Table S10) is
centered on nodes of genes that are playing a role in the
inflammatory response (CD3) and oxidative stress (GST).
Pathways associated with genes selectively changed by
the exposure to the Ab-Al complex
We performed a pathway analysis of the genes selectively
modulated by the exposure to the Ab-Al complex. This analysis
reveals two main pathways that are likely involved in AD.
Gene Expression of SH-SY5Y Cells Exposed to Ab-Al
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e15965
The first pathway pertains to the regulation of intracellular Ca2+
([Ca2+]i) homeostasis, a mechamism that has functional consequences
on neuronal and dendritic/spine loss as well as in the maintaining of
Long-term Potentiation (LTP) and memory (Figure 4). This pathway
shows the upregulation of genes encoding for key proteins like
glutamate receptor subunits (GRIN1,GRIN2c, andGRIA), CAMKII,
HDAC, MEF2, Actin alfa, as well as NCX, the gene encoding for the
Na+-Ca2+ exchanger, PMCA that encodes for the Na+-Ca2+/ATPase
pump as well as nAchR that encodes for the nicotinic receptor, a key
receptor involved in AD [15]. Interestingly, this pathway also shows a
series of downregulated genes that are critical for synaptic plasticity.
Among these genes, we find CALM, the gene encoding for calmodulin,
a key regulator of transcription, memory and neuronal survival, PKC,
as well as GLUR5 (i.e.: GRIK1) that encodes for a kainate receptor
subunit, CASQ encoding for calsequestrin, a mitochondrial calcium-
binding protein [16], CREB encoding for the Cyclic AMP Response
Element Binding, a key transcriptor factor involved in neuronal
plasticity and LTP. We also find CBP that encodes for the CREB-
binding protein and is a co-activator interacting with CREB, thereby
reinforcing the modulation of LTP. Moreover, we find a down-
expression of NFTAc encoding for a component of the nuclear factor
of activated T cells DNA-binding transcription complex. Intriguingly,
in cultured neurons as well as in the adult mouse brain, NFTA
activation promotes dendritic alterations and spine loss [17]. In
addition we see a downregulation of DSCR1, an oxidative stress-
response gene that represses calcineurin (CaN), ultimately leading to
increased CaN activity, a phenomenon that has been shown to induce
synaptic dysfunction and memory impairment [18].
Finally, we find a downregulation of CRAC that encodes for
activation of store-operated Ca2+ release-activated Ca2+channels.
CRACs are critical channels controlling capacitative Ca2+ entry
and the maintaining of Ca2+ homeostasis when the cation is
depleted from intracellular stores [19].
The second pathway inferred by IPA is functionally related to
the first one and shows genes that are controlling glutamatergic
neurotransmission. In the second pathway we find upregulated
genes encoding for NMDA and AMPA receptor subunits like
GRIN, GRIA and GRID as well as downregulated genes, like
HOMER, calmodulin. Downregulated are also SLC1A 6/7 and
SLC1A 2/3, that encode for glutamate transporters as well as
GRIK a gene encoding for kainate receptors (Figure 5).
The involvement of these pathways in AD pathogenesis is
further analyzed below in the discussion.
Discussion
The IPA-generated network and pathway analysis reveals that,
compared to Ab or Al alone, the Ab-Al complex selectively
Table 1. List of AD-related genes (http://www.alzgene.org) that are selectively overexpressed upon exposure to Ab-Al compared
to exposures to Ab or Al alone.
Gene symbol
Ab
(Log2 ratio)
AbAl
(Log2 ratio)
Al
(Log2 ratio) RefSeq Description
AR 20.15 1.94 0.42 NM_000044 Androgen receptor
NOS2A 20.21 1.87 20.14 NM_000625 Nitric oxide synthase, inducible (NOS, type II)
VDR 0.19 1.77 0.17 NM_000376 Vitamin D3 receptor (VDR)
NGFR 20.12 1.18 21.12 NM_002507 Tumor necrosis factor receptor
CCNT1 0.28 1.09 20.06 NM_001240 Cyclin T1
IDE 20.02 1.05 20.16 NM_004969 Insulin-degrading enzyme
FTSJ3 0.13 1.02 0.41 NM_017647 FtsJ homolog 3
KCNJ6 20.53 1.02 0.36 NM_002240 G protein-activated inward rectifier potassium channel 2
NOS1 0.43 1.01 20.74 NM_000620 Nitric-oxide synthase, brain (NOS, type I)
PLCE1 0.27 0.99 0.34 NM_016341 pancreas-enriched phospholipase C
PRKAA1 20.02 0.93 0.09 - 59-AMP-activated protein kinase, catalytic alpha-1 chain
SLC6A3 0.22 0.90 0.35 NM_001044 Sodium-dependent dopamine transporter
MYH8 0.38 0.85 20.21 NM_002472 Myosin heavy chain, skeletal muscle, perinatal
FDPS 20.22 0.84 0.13 NM_002004 Farnesyl pyrophosphate synthetase
HMOX1 0.15 0.83 0.30 NM_002133 Heme oxygenase 1
CNTF 0.22 0.82 0.03 NM_170768 Ciliary neurotrophic factor
SOS2 0.32 0.79 20.69 NM_006939 Son of sevenless protein homolog 2
ACSL4 0.40 0.74 20.02 NM_004458 Long-chain-fatty-acid–CoA ligase 4
ADRB1 0.35 0.73 20.28 NM_000684 Beta-1 adrenergic receptor
ABCA1 0.05 0.72 0.45 - ATP-binding cassette, sub-family A, member 1
APOM 0.00 0.59 20.63 NM_019101 Apolipoprotein M
GLP1R 0.36 0.55 0.21 NM_002062 Glucagon-like peptide 1 receptor precursor
CH25H 20.14 0.55 20.47 NM_003956 cholesterol 25-hydroxylase
ECE1 20.06 0.51 20.07 NM_001397 Endothelin-converting enzyme 1
ATF7 20.07 0.51 20.04 NM_006856 Cyclic-AMP-dependent transcription factor
F13A1 0.30 0.50 0.22 - Coagulation factor XIII A chain precursor
doi:10.1371/journal.pone.0015965.t001
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modulates the expression of genes that can have an important role
in AD pathogenesis.
For clarity, we have broken down the discussion on specific
genes, analysis of networks, and pathways.
Gene analysis
Upregulated genes of the first network. TGFB1 encodes for
the Golgi-specific brefeldin A-resistance guanine nucleotide exchange
factor 1 protein that forms a heteromeric complex with the TGF-beta
receptors type II and participates in the transforming growth factor
(TGF)-1 signaling cascade. TGF Beta -1 can have a role in AD as
experiments in AD transgenic mice have indicated that the protein
promotes a marked reduction in brain accumulation of AbPP through
the activation of microglia [20]. Thus, TGFB1 overexpression may
promote a protective compensatory inflammatory response that can
reduce the brain amyloid load.
ARRB1 belongs to the Beta-arrestin family and modulates the
desensitization and endocytosis of seven-transmembrane recep-
tors, 7TMRs, the largest group of plasma membrane receptors
[21]. In the context of AD, ARRB1 may be critically important as
it can modulate the endocitosys of metabotropic glutamate
receptors, mGluRs, and affect glutamatergic neurotransmission
[22]. Furthermore, ARRB1 can interact with APLP1in promoting
neuronal apoptosis [21].
APLP1 is a member of a protein family that also includes the Ab
precursor protein (AbPP). APLP1 encodes for a membrane-
associated glycoprotein that, like AbPP, is cleaved by secretases.
While AbPP has received much attention in the context of AD as
the protein is involved in neurite outgrowth, cell adhesion,
synaptogenesis, synaptic plasticity and neuroprotection [23], far
less studies have investigated the role of APLPs. Despite a high
degree of similarity with AbPP, APLP1 lacks an amyloidogenic
domain; however, APLP1 has been found in the amyloid plaques
of AD brains [24,25,26]. Furthermore, given its synaptic
localization, APLP1, like AbPP, can be involved in synaptogenesis
and synaptic plasticity. APLP1 also influences AbPP endocytosis
[27] and an accumulation of APLP1 has been reported in neuritic
plaques of the hippocampus of AD patients [24].
Upregulated genes of the second network. Nitric oxide
synthase (NOS) generates nitric oxide (NO) and is present in the
CNS in three isoforms: neuronal Type-1 NOS (nNOS), inducible
Type-2 NOS (iNOS), and endothelial Type-3 NOS (eNOS). iNOS
is induced in astrocytes near the senile plaques [28] and, in
transgenic AD animal models, its overexpression is an early event
that precedes the appearance of amyloid plaques [29]. An
increased NOS-mediated NO production can promote neuronal
dysfunction and/or cell death. NO is also a major determinant of
NMDAR-dependent neurotoxicity and, as such, can be a key
player in the excitotoxic neuronal loss found in AD [30,31].
Clathrin-is a key protein that regulates endocytosis. In the context
of AD, several studies indicate that the endocytotic machinery
plays an active role in AbPP [32]. Furthermore, clathrin-mediated
endocytosis is also a regulator of the internalization of a subtype of
ionotropic glutamate receptor, the AMPA receptor (AMPAR),
Table 2. List of AD-related genes (http://www.alzgene.org) that are selectively downexpressed upon exposure to Ab-Al compared
to exposures to Ab or Al alone.
Gene Symbol
Ab
(Log2 ratio)
AbAl
(Log2 ratio)
Al
(Log2 ratio) RefSeq Description
OLIG2 20.09 21.93 0.68 NM_005806 Oligodendrocyte transcription factor 2
NAT1 20.39 21.68 20.24 NM_000662 Arylamine N-acetyltransferase 1
APOC3 0.67 21.00 20.35 NM_000040 Apolipoprotein C-III precursor
WNT8B 0.54 20.96 0.68 NM_003393 Wnt-8b protein precursor
MME 20.20 20.93 20.26 NM_007289 Neprilysin
APOD 0.36 20.88 20.08 NM_001647 Apolipoprotein D precursor
LRP1 20.13 20.84 20.35 NM_002332 Low-density lipoprotein receptor-related protein 1 precursor
AHSG 20.49 20.78 20.47 NM_001622 Alpha-2-HS-glycoprotein precursor
GAB2 20.13 20.78 20.05 NM_080491 GRB2-associated binding protein 2
MMP1 20.20 20.73 0.27 NM_002421 Interstitial collagenase precursor
TCN1 0.25 20.71 20.05 NM_001062 Transcobalamin I precursor
MYST4 20.18 20.68 0.15 NM_012330 MYST histone acetyltransferase
TNFRSF1B 1.06 20.67 0.16 NM_001066 Tumor necrosis factor receptor superfamily member 1B precursor
ANXA8 0.28 20.63 0.22 - Annexin A8
CD36 0.36 20.61 0.35 NM_001001548 Platelet glycoprotein IV
CTSS 20.36 20.60 1.25 NM_004079 Cathepsin S precursor
ESR1 1.01 20.60 20.26 NM_000125 Estrogen receptor
SFRP5 0.43 20.58 0.09 NM_003015 secreted frizzled-related protein 5
PIK3R1 20.43 20.56 20.50 NM_181524 Phosphatidylinositol 3-kinase regulatory alpha subunit
POU2F1 0.32 20.54 0.34 NM_002697 POU domain, class 2, transcription factor 1
TNF 0.01 20.52 0.39 NM_000594 Tumor necrosis factor precursor (TNF-alpha)
THRA 20.48 20.52 20.35 NM_003250 Thyroid hormone receptor alpha
FCER1G 20.26 20.52 20.01 NM_004106 High affinity immunoglobulin epsilon receptor gamma-subunit precursor
doi:10.1371/journal.pone.0015965.t002
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that critically modulates the efficacy of glutamatergic
neurotransmission as well as LTP and Long-term Depression
[33]. Modulation of synaptic activity impinges in amyloid
metabolism as sustained synaptic activation leads to a rapid
increase in Ab levels in brain interstitial fluid (ISF) while a
depressesed synaptic transmission reduces Ab ISF levels [34].
C-Jun is a component of the AP-1 protein complex and AP-1 is
activated downstream of c-Jun [35]. The c-Jun N-terminal Kinase
(JNK)-AP1 signaling pathway plays a key role in AD by affecting
gene expression, cell proliferation, the inflammatory response as
well as neuronal apoptosis [36]. In AD brains, c-Jun phosphor-
ylation promotes the induction of JNK activity, a phenomenon
Figure 1. Biological functions associated with genes selectively changed by the exposure to the Ab-Al complex. Bar charts show key
biological functions associated with genes found to be selectively either overexpressed (A) or downexpressed (B) in SH-SY5Y cells exposed to Ab-Al.
doi:10.1371/journal.pone.0015965.g001
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that eventually triggers the pathogenic processing of AbPP by
inducing its hyperphosphorylation [37]. Furthermore, the AD-
related oxidative stress stimulates the activation of JNK, p53, and
p38 which leads to apoptotic neuronal death [27]. Interestingly,
AP1 is also involved in inflammation as experiments in cultured
human brain endothelial cells exposed to Ab, indicate that AP1
upregulates the expression of inflammatory genes like MCP-1,
GRO, IL-6, and IL-1b [35]. Finally, AP1is also activated in the
cerebral amyloid angiopathy associated with AD [35]. Thus, C-
JUN and AP1 upregulation can have a role in the neurovascular
inflammation triggered by Ab oligomers.
Upregulated genes of the third network. Furin
participates in the amyloid metabolism by regulating the
cleavage of AbPP through a-secretase activation [38], thereby
reducing Ab production. The process is mediated by promoting
the maturation of A Dysintegrin And Metalloproteases 10
(ADAM10) and ADAM 17/tumor necrosis factor-a converting
enzyme (TACE), two enzymes that have a secretase activity
[39,40]. Interestingly, furin mRNA levels have been shown to be
reduced in the brain of AD patients and transgenic AD mice [41].
The Myocyte enhancer factor 2 (MEF2) is a Ca2+-regulated
transcription factor that promotes neuronal survival [42] and is
also a key modulator of activity-dependent synaptic development
[43]. MEF2C is a transcription factor that facilitates hippocampal-
dependent learning and memory in rodents. MEF2C is positively
modulated by BDNF [44] and regulates the synaptic number as
well the efficacy of synaptic connections [45].
NR41 is a member of a pool of 9 neuroprotective genes called
Activity-regulated Inhibitor of Death (AID) genes that have been
shown to promote neuronal survival by making neuronal
mitochondria more resistant to cellular stress [46].
IDE encodes the insulin degrading enzyme which, beside its role
in insulin metabolism plays its part in modulating brain Ab levels
as the enzyme, with lower affinity than insulin, also recognizes Ab
as a substrate [47,48]. Several studies have demonstrated the role
of the IDE gene in AD, in fact genome-wide linkage analysis of
families of late onset AD patients showed significant linkage peaks
mapped near the IDE locus [10q23.33; [49]]. Moreover, a recent
study showed a strong association between certain IDE polymor-
phisms that are able to modify brain IDE transcription levels and
the development of late onset AD [50,51]. Finally, IDE has also
been found to be decreased upon aging and AD [52].
Histone deacetylases (HDACs) belong to a family of proteins
that by catalyzing the deacetylation of histones plays an important
role in the epigenetic brain regulation of transcription, apoptosis as
well as learning and memory [53,54]. Interestingly, many
neuroprotective genes such as BDNF, GDNF, HSP70, a-
synuclein, Bcl-2, Bcl-XL, and p21 are modulated by HDAC
Table 3. Central nervous system (CNS) genes present in the functional groups associated with overexpression promoted by the
exposure to the Ab-Al complex.
Category p-value Molecules
Amino Acid Metabolism 2,23E-04-3,86E-02 NOS1, SLC6A8, TGFBR1, ATG7, TDO2, HIPK3, BHMT, SLC1A3, NAGS, IDO2, SLC7A4, BDKRB2, FTCD, SBK1, SLC16A2,
GNRH1, NOS2, SLC7A6, ARG1
DNA Replication,
Recombination, Repair
5,41E-04-3,86E-02 NOS1, BDKRB2, DMC1, NOS2, NUDT15
Lipid Metabolism 5,57E-04-3,86E-02 PTGIS, RAB27B, PLA2G3, TNFSF10, ARSA, CES1 (includes EG:1066), PLCD1, BDKRB2, HMOX1, F2RL3, AR, PLCE1,
ARRB1, INPP5F, PLA2G2D, ACP6, NGFR, GPLD1, GNRH1, KISS1, VDR, NOS2, LPP
Cellular Function and
Maintenance
1,19E-03-3,86E-02 NOS1, SPIB, C3, STX6, SRL, CD3D, JUN, CAMK2A, CBL, AR, CXCL13, NGFR, S1PR1, GNRH1, KIT, PRDM1, VDR, FASLG
Cell Death 1,49E-03-3,86E-02 NOS1, FURIN, TGFBR1, ATF7, NEFL, TNFSF10, HMOX1, YES1, JUN, AR, PDCD1, NGFR, KIT, PRR13, NOS2, FASLG,
EBAG9, ITGA2, SLC8A3, F13A1, MLANA, CLCF1, HMGA2, CTF1, NR4A1, HAS2, RARRES3, ARG1
Cell Morphology 1,49E-03-3,86E-02 NOS1, IFT88, KALRN, LMO2, RP1, PROX1, PRKG1, LAMB2, BDKRB2, AR, ESPN, NGFR, EFNB1, EFNA5, CNTNAP1, VDR,
CALML3, MARCO, ARG1
Cell Signaling 1,49E-03-3,86E-02 NOS1, DSPP, STX6, F13A1, TNFSF10, KCNIP3, IL12RB2, BDKRB2, HMOX1, CAMK2A, JUN, S1PR1, VDR, NOS2, FASLG,
ATP2B4, ARG1
Nervous System
Development and
Function
1,49E-03-3,86E-02 NOS1, POU3F1, NODAL, SLC1A3, EMX2, PRKG1, EN1, CAMK2A, AR, ABR, APLP1, EFNA5, NGFR, MAL, CDK5R2, NHLH2,
ECE1, CNTNAP1, NOS2, IRX3, ZBTB16, FRS2, IFT88, KALRN, ARSA, CLCF1, LAMB2, SEPP1, PYGO2, CTF1, ARHGEF10,
GNRH1, S1PR1, PTH2, ARG1, ATOH7
Cellular Compromise 1,79E-03-3,86E-02 NOS1, C3, SLC1A3, TNFSF10, PRKG1, LIMK1, BDKRB2, HMOX1, JUN, NGFR, EFNA5, EFNB1, GNRH1, KIT, CEP250, TRRAP
Neurological Disease 5,25E-03-3,86E-02 SNTG1, KIF13B, FURIN, CACNA1H, NKAIN3, IDE, MYH7B (includes EG:57644), TESC, ILDR1, CAMK2A, KIF13A, APLP1,
SLC16A2, HS6ST3 (includes EG:266722), HIPK1, ZBTB16, FRS2, PTGIS, SLC24A4, CYP7B1, ATG7, APOM, KALRN, LPHN3,
GPR15, IL12RB2, ZNF215, MED12, AIG1, RASL12, ARHGDIB, NRXN1, GPC5, SRGAP3, PODXL2, PCSK1, SCN1B,
ST3GAL1, EHMT2, NEK4, CXCR6 (includes EG:10663), HAS2, CYCS (includes EG:54205), NR3C2, RCVRN, TSNARE1,
FLJ45684, ITGA2B (includes EG:3674), UBASH3A, SCD5, MYH8, HLA-DQA1, SLC1A3, HSPB8, TNFSF10, TMEM185A,
HTR1D, SEPT11, PRKG1, CORO2B, TYW1, SLC6A3, MAFG, PLCD1, CGNL1, YES1, PRKX, AR, ARRB1, ADRB1, JUN, TRHDE,
GRID1, NGFR, EFNA5, MAL, ACSL4, LY75, DEGS2, EEF2K, VDR, MUC2, LPP, TRIM67, DNER, FKTN, CCDC6, CXCL6,
TAAR6, CXORF48, SVIL, GLE1, GLT25D2, NR4A1, S1PR1, RAB3GAP2, COL4A4 (includes EG:1286), AK3L1, ACVR2A,
ST8SIA3, STRN, T, CLTB, EDA, TRIM31, USH1C, LIMK1, SHC4, GGA1, ESPN, GRIN2C, BRSK1, SGPP2, SLC2A9, NUPR1,
CNTNAP1, ACTA1, IFT88, NDUFB3, SEC14L3, C3, SESN3, PSMF1, MAST4, MYH14, ARID1B, COL2A1, CCDC129, ARSA,
CHRND, SLC6A11, C7ORF57, SLC22A5, GNRH1, RARRES3, RFX2, CA11, KCNJ6, C1ORF21, CNIH3, SYNPR, AGTR1,
LRRC8B, ARG1, NOS1, POU3F1, CCIN, NEFL, GPR156, FLRT2, PCDH19, EMX2, ENOX1, KIAA1409, ZNF225, OPRL1,
HMOX1, PLA2G4E, FXYD7, LRGUK, KIT, NAMPT, NOS2, LASP1, CPNE9, C6ORF15, BTLA, RPGRIP1, WDR25, SCN1A, HLA-
DMA, COL5A2, DSPP, MDGA1, RP1, SLC8A3, TRPA1, F13A1, CCDC85A, KCNIP1, CLCF1, PLXND1, AFF1, FDPS, SEPP1,
ARHGEF10, DIP2C, HERC6, AKAP10, FOXI1, BCAS1, GRIA3
RNA Damage and Repair 3,86E-02-3,86E-02 NOS2
doi:10.1371/journal.pone.0015965.t003
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inhibition. Furthermore, several findings indicate that HDAC
inhibition in AD animal models restores the histone hypoacetyla-
tion, increases synaptic plasticity, decreases Ab production and tau
hyperphosphorylation, improves learning and memory and
reverses spatial memory deficits [55,56]. Finally, experimental
data show that overexpression of HDAC9 and HDRP, a spliced
form of HDAC9, can serve a role as an antiapoptotic molecule by
binding and inhibiting the apoptosis-inducing MAP kinase, JNK
[57].
Upregulated genes of the fourth network. Phospholipase
A2 (PLA2) participates in the metabolism of fatty acids [58,59].
PLA2 modulates several signaling pathways that link oxidative
stress and proinflammatory cytokines to the release of arachidonic
acid and the synthesis of eicosanoids. PLA2 is also involved in
intracellular membrane trafficking, differentiation, proliferation,
and apoptosis [60]. The role of PLA2 in AD is complex. Reduced
activity of specific subtypes of intracellular PLA2 (cPLA2 and
iPLA2) are found in AD and thought to participate in the cognitive
decline and neuronal loss associated with the disease [61]. On the
other hand, PLA2 has been found to be strongly overexpressed in
AD, suggesting that, overall, this gene may have a negative effect
by promoting the inflammatory response of the AD brain [62].
The Calcium/calmodulin-dependent protein kinase II, CaM
kinase II, is the most abundant protein kinase in the brain and by
controlling the trafficking of AMPAR subunits [63] a key
modulator of LTP and neuronal plasticity [64]. In the context of
AD it is worth noting that the CaMKII synaptic pool is reduced in
cultured cortical neurons obtained from AbPP transgenic mice, a
phenomenon that promotes the loss of synaptic AMPARs and the
impairment of glutamatergic transmission [65]. As far as NMDA
Table 4. Central nervous system (CNS) genes present in the functional groups associated with downexpression promoted by the
exposure to the Ab-Al complex.
Category p-value Molecules
Cell-To-Cell Signaling
and Interaction
1,44E-06-2,05E-02 TAF4B, GAB2, CD3E, TGFBR3, POU2AF1, PIK3R1, LAT2, GHSR, FOXP3, CD1E, CD163, TREM2, STAB2, F2, PTPRC, HRH1,
ALDH1A1, HAVCR1, PIK3CG,PPBP, TAS1R3, CD226, OSM, KLRC3, SCN5A, PTX3, KIR2DS3, GLRA2, OPRM1, CD200R1,
SNAI1, OPCML, PLEC, THRA, CLEC5A, FYB, LAX1, TLR2, TNFSF8, PNLIPRP2, CDH1, PGLYRP4, UMOD, GJA3, IL10RA,
PECAM1, BCL2A1, TNF, LCP2, TCL1A, ALK, ADM, MSR1, PLA2G10, KLRF1, ADIPOQ, RHOH, WNT7A, C5AR1,
PDCD1LG2,APOC3, IL2, TAOK2, CD38, PRKCE, S100A8, IL27RA, MMP1, RNASE2, RELB, AHSG, MGAT5, CD36, GNAQ,
ERBB3, IL1R1, IL20RB, ID3, CCL7, BCL10, CXCL12, FCER1G, DEFB129, NFATC2, TIRAP, LRP1, IFNA1, PRKCB
Inflammatory Response 5,08E-06-2,12E-02 PIK3R1, TGFBR3, CD1E, AFAP1L2, PTPRC, HRH1, CTSS, PIK3CG, PPBP, ALPP, RAB27A, CD200R1, PLEC, CLEC5A, CDH1,
HLA-DRB3, IL10RA, TNF, LCP2, MME, ADM, PLA2G10, KLRF1, ADIPOQ, FOXN1, TRPM2, NFIL3, C5AR1, TAOK2, CD38,
PRKCE, IL27RA, TNFRSF1B, CFP, MMP1, RNASE2, ALOX15, MX2, AHSG, GNAQ, ALOX5AP, BCL10, FCER1G, HRH4, TIRAP,
LRP1, IFNA1, PRKCB, GAB2, RNASE6, CD3E, POU2AF1, SOCS6, LAT2, GHSR, FOXP3, LYZ, TREM2, CD163, IFNA6, F2,
STAB2, MTTP, HAVCR1, CD226, PRR13, OSM, MGLL, SCN5A, PTX3, OPRM1, CLEC1A, LAMA2, THRA, PDE4B, HHIP, FYB,
LAX1, MECOM, TLR2, PGLYRP4, UMOD, WFDC12, PECAM1, RAG1, IL22RA2, ESR1, TCL1A, MSR1, AMBP, PDCD1LG2,
LYST, IL2, PRKAR1B, S100A8, RELB, CD36, MGAT5, IL1R1, IL20RB, APOL1, CCL7, CXCL12, PI3, SLC1A2, NFATC2, DEFB129
Cellular Development 7,11E-05-2,12E-02 HTR2B, PIK3R1, IL13RA2, PTPRC, HRH1, OLIG2, MOS, MCOLN3, PIK3CG, WWOX, BGLAP, HEYL, RAB27A, POU4F1,
PCDH15, PITX2, OTX2, ATF2, TNFSF8, CDH1, SOSTDC1, CD5, RXFP1, IL10RA, RGL2, BCL2A1, ISL2, TNF, LCP2, CA2,
ADIPOQ, TWSG1, FOXN1, EP300, CLEC11A, C5AR1, WNT7A, CD38, IL27RA, TNFRSF1B, MMP1, RNASE2, ALOX15, USH1G,
POU4F2, CACNB4, TAF8, GNAQ, HIP1, ID3, SPDYA, BCL10, FCER1G, TIRAP, CHRDL1, PTPN22, IFNA1, POU5F1, PRKCB,
TCF21, TAF4B, GAB2, CD3E, POU2AF1, CUL4A, SKI, LAT2, FOXP3, RNASE1, EOMES, CD163, TREM2, MEN1, CD8B, IFNA6,
F2, USH1C, MBNL3, ALDH1A1, HAVCR1, CD226, MRAS, OSM, FLG, ZMYM2, TBX19, LAMA2, THRA, CITED1, LAX1, MLPH,
MECOM, TLR2, GJA3, RAG1, PECAM1, SF3B4, ESR1, TCL1A, FGF5, GATA1, MSR1, PICALM, CHRDL2, RHOH, BLK, IL2,
GNAT2, RELB, EMX1, CD36, ERBB3, HES3, IL1R1, NKX2-5, CXCL12, LINGO1, SLC1A2, NFATC2
Molecular Transport 1,47E-04-2,15E-02 GAB2, MRGPRD, CACNG1, CD3E, PIK3R1, LAT2, UCP1, GHSR, LYZ, F2, MTTP, PTPRC, GUCA2B, HRH1, OSTALPHA,
PIK3CG, PPBP, TAS1R3, OSM, MGLL, MCHR2, ALPP, CASQ2, CHRM2, GRIK1, MAS1, RAB27A, SLC1A6, OPRM1, CLEC5A,
NPY5R, MLNR, TLR2, ACADL, CD5, MCHR1, PECAM1, OSTBETA, ESR1, TNF, LCP2, FGF5, APOD, ADM, CA2, HOMER2,
MSR1, SLC1A5, PLA2G10, KLRF1, ADIPOQ, RAPGEF4, EP300, TRPM2, OSCAR, CLEC11A, WNT7A, C5AR1, IL2, APOC3,
GNAT2, IBTK, PRKCE, CD38, S100A8, AVPR1B, MMP1, ALOX15, CNGA2, NOX5, SLC25A2, GNAQ, CD36, ALOX5AP, HIP1,
IL1R1, TRPC7, EPB41, CCL7, CXCL12, FCER1G, NFATC2, NR5A2, SLC1A2, DGAT1, HRH4, LRP1, PRKCB
Cell Death 4,82E-04-2,09E-02 TCF21, TAF4B, GAB2, CRYAB, CD3E, POU2AF1, PIK3R1, UCP1, TREM2, F2, PTPRC, HAVCR1, PIK3CG, PPBP, CD226, OSM,
PTX3, POU4F1, TNFSF8, POU2F1, UMOD, CD5, BCL2A1, ESR1, TNF, ALK, FGF5, GATA1, MSR1, PLA2G10, ADIPOQ, BOK,
C8A, BRAF, CLEC11A, NFIL3, PDCD1LG2, IL2, PRKCE, S100A8, IL27RA, TNFRSF1B, SLC4A1, POU4F2, CD36, ERBB3, HIP1,
IL1R1, ID3, BCL10, CXCL12, LINGO1, FCER1G, SLC1A2, LRP1, PRKCB
Lipid Metabolism 8,28E-04-1,97E-02 ADM, CYP4F2, PLA2G10, PIK3R1,UCP1, LGALS4,MTTP, HRH1,APOC3, IL2, PIK3CG, PPBP, CYP7A1, PRKCE, S100A8, MGLL,
AGPAT9, ALPP, CHRM2, CYP4A11, AVPR1B, HSD3B2, MAS1, GNAQ, CD36, ALOX5AP, IL1R1, NPY5R, TLR2,
PNLIPRP2,CXCL12, FCER1G, NFATC2, NR5A2, OSTBETA, DGAT1, ESR1, TNF, LRP1, PRKCB, APOD
Neurological Disease 8,28E-04-2,17E-02 MME, BTN1A1, F2, USH1C, HRH1, PDCD1LG2, ALDH1A1, IL2, CTSS, MOS, KCNC1, PRKCE, IL27RA, TNFRSF1B, CHRM2,
USH1G, CNTN1, OPRM1, CACNB4, MGAT5, GNAQ, PCDH15, HIP1, IL1R1, NPY5R, OTX2, TLR2, GABRG2, CD5, CXCL12,
SLC1A2, PECAM1, RAG1, FOXI1, C6, HRH4, TNF, ESR1, LRP1
Free Radical Scavenging 1,46E-03-1,47E-02 GAB2, NOX5, SHANK2, CD36, UCP1, THRA, FNTB, F2, TLR2, HK1, IL2, PIK3CG, CXCL12, PPBP, FCER1G, PECAM1, TNF,
LCP2, PRKCB
Cellular Assembly and
Organization
1,99E-03-1,82E-02 RAB27A, CRYAB, CD3E, SNAI1, PLEC, HIP1, F2, MLPH, CDH1, C5AR1, CXCL12, FCER1G, PECAM1, ESR1, LRP1
Post-Translational
Modification
4,14E-03-1,82E-02 ADM, CNTN1, CD3E, CD36, HIP1, MEN1, EP300, AFAP1L2, PTPRC, FAM129A, CD5, IL2,
DNA Replication,
Recombination, Repair
1,07E-02-1,82E-02 BRAF, GPHA2, NOX5, GATA1, POU2F1, IL2, PIK3CG, MEN1, ESR1, TNF, F2, ATF2
doi:10.1371/journal.pone.0015965.t004
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Figure 2. Top networks generated by IPA associated with genes selectively overexpressed by the exposure to the Ab-Al complex.
Genes in red show increased expression in SH-SY5Y cells exposed to Ab-Al when compared with untreated SH-SY5Y cells. Arrows indicate that a
molecule acts on another while lines indicate that a molecule binds to another. Small histograms indicate changes in gene expression.
doi:10.1371/journal.pone.0015965.g002
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Figure 3. Top networks generated by IPA associated with genes selectively downexpressed by the exposure to the Ab-Al complex.
Genes in green show decreased expression in SH-SY5Y cells exposed to Ab-Al when compared with untreated SY5Y cells. Arrows indicate that a
molecule acts on another while lines indicate that a molecule binds to another. Small histograms indicate changes in gene expression.
doi:10.1371/journal.pone.0015965.g003
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receptor subunits, IPA shows a very intriguing upregulation of two
specific subunits, GRIN1 and GRIN2c, and the functional
implications of such changes are discussed in the pathway section.
Downregulated genes of the first network. The homer
family is a class of postsynaptic scaffolding proteins that regulate
the structural and functional integrity of synapses [66]. Homer I is
particularly important in the modulation of the trafficking of
mGluRs [67] as well as in the regulation of dendritic spine
formation [68]. Homer is particularly relevant in the modulation
of mGluR-dependent LTD [69,70], can also participate in the
stabilization of the post synaptic density (PSD), and influences the
endocytosis of NMDARs and AMPARs [66,71].
ESR1 encodes for the estrogen receptor alpha, ER-a. ER-a is
present in AD-affected regions like the hippocampus, the basal
forebrain, and amygdala [72] and helps in maintaining cholinergic
neurotransmission [73,74]. A postmenopausal decrease in estrogen
levels is a well-known AD co-risk factor as the hormones favor the
brain catabolization of Ab by regulating the expression of
neprilysin, an enzyme that promotes Ab degradation [75].
Moreover, ER-a polymorphisms are associated with both familial
and sporadic AD [76] and decrements of the receptor mRNA
splice variants have also been detected with higher frequency in
AD female subjects [77]. These changes may help to explain why
estrogen-replacement therapy fails to rescue cognitive functions in
AD patients [78].
The transcriptional co-activator EP300 plays an important role
in regulating gene expression in a number of different cell types
[79] and is regulated by Presenilin 1 (PS1), an endoplasmic
reticulum/Golgi transmembrane protein whose mutations have
been associated with early-onset familial Alzheimer’s disease
([FAD; [80]). P300 promotes a signalling mechanism that is
important for long-term memory formation and neuronal survival.
The regulation of p300 activity by wild-type PS1 and not by
mutant PS1 indicates a partial loss of function in AD that may lead
to memory loss and neurodegeneration [79].
Downregulated genes of the second network. CDH1
belongs to the cadherin superfamily and encodes for cadherin1, a
protein that is involved in neuronal apoptosis. Depletion of
cadherin 1 leads to apoptotic neuronal death by favoring the re-
entry or reactivation of the cell cycle [81], an important
phenomenon as aberrant cell cycle reactivation has been
described in AD neurons. Finally, it must be noted that, in
cortical cultured neurons, overexpression of Cdh1 results in
neuroprotection against Ab toxicity [82,83].
Actins are key proteins involved in the maintenance of the
cytoskeleton as well as in the stabilization of synapses [84]. Actin
Figure 4. IPA-generated pathways associated with genes selectively over or downexpressed upon exposure to Ab-Al: modulation
of glutamatergic transmission and synaptic plasticity. IPA-generated pathways as resulting from the analysis of gene changes in SH-SY5Y cells
exposed to the Ab-Al when compared with untreated SH-SY5Y cells. Overexpressed genes are depicted in red, downexpressed genes are in green
while genes in white are the ones inferred by IPA.
doi:10.1371/journal.pone.0015965.g004
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filaments can have a particular pathogenic role in AD as they are
associated with apolipoprotein E, AbPP, PS1, and the tau protein
[46,85]. Actin rods have been shown in autoptic samples from AD
patients. Moreover, actin is associated with phoshophorylation of
the synaptic protein, cofilin, and participates in the synaptic
structural changes that underlie LTP in vivo and in vitro [86]. In
summary, a down expression of actin may affect synaptic efficacy
and ultimately impair the molecular machinery that is responsible
for learning and memory.
Downregulated genes of the third network. PKC can play
an important role in AD as its activation promotes the non-
amyloidogenic cleavage of AbPP by directly activating the a-
secretase pathway or through an upstream involvement of the
MAP kinases ERK1/2 [87]. PKC also inhibits the activity of the
beta-site AbPP-cleaving enzyme 1, BACE-1, thereby reducing Ab
biosynthesis [88]. PKC dysfunction can also interfere with synaptic
functioning. Phosphorylation of key synaptic proteins like adducin,
stathmin and myristoylated alanine-rich C-kinase substrate
(MARCKS) by PKC and Ca2+/calmodulin-dependent protein
kinase II (CaMKII) can severely affect spine integrity.
Interestingly, the AD brain appears to suffer from a deficit in
PKC activation rather than from a defective PKC expression [89].
Furthermore, a decrease in PKC activation leads to enhanced
levels of phosphorylated tau through a reduced PKC-mediated
inhibition of GSK-3b [90].
The Shank family of synaptic proteins are particularly
important as molecular scaffolds that control the integrity of the
postsynaptic density (PSD) and handle the synaptic trafficking of
glutamate receptor subunits [91]. A decrease in Shank expression
can favor a dysfunctional synaptic rearrangement of NMDA and
AMPA receptors and ultimately impair LTP and synaptic
efficiency.
Downregulated genes of the fourth network. CD3
encodes for the T-cell receptor zeta, a subunit of the T-cell
Figure 5. IPA-generated pathways associated with genes selectively over or downexpressed upon exposure to Ab-Al: modulation
of Ca2+ homeostasis. IPA-generated pathways as resulting from the analysis of gene changes in SH-SY5Y cells exposed to the Ab-Al when
compared with untreated SH-SY5Y cells. Overexpressed genes are depicted in red, downexpressed genes are in green while genes in white are the
ones inferred by IPA.
doi:10.1371/journal.pone.0015965.g005
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receptor-CD3 complex which is responsible for recognizing
antigens in different intracellular signal-transduction pathways.
CD3 positive T-cells induce microglial activation and actively
participate in the AD development [92]. However, it must be
noted that a significant decrease of CD3(+) lymphocytes can also
be responsible for the general decline of immune activity that is
observed in AD [78].
In the brain, the glutathione transferase (GST) promotes the
cellular response that protect against oxidative injury [93].
Decreased GST activity has been found in the brain of AD
patients and has been linked to AD-related neuronal death
[94,95]. Furthermore, GST polymorphisms, such as homozygous
deletions in GSTM1 and GSTT1 genes, are encoding for defective
proteins with less efficient enzymatic activities. These GST
polymorphisms have been found with higher frequency in patients
affected by late onset AD [96].
Network analysis
Upregulated genes like ARRB1, NOS, c-JUN, and PLA2 fit in
networks that are linked to neuronal apoptosis. In line with this
trend, we also found a parallel downregulation of some
neuroprotective and antiapoptotic genes like EP300, CDH1, and
GST. Furthermore, our networks analysis indicates that Ab-Al can
promote changes of genes like APLP1, Furin, Clathrin, and IDE
that favor alterations of AbPP processing and genes like CaMkII,
GRIN1, and GRIN2c that modulate glutamatergic neurotrans-
mission. We also detected changes in c-JUN and PLA2 that can
influence the inflammatory response as well as an overexpression
of TGFB1, MEF2, and NR41 that can promote a protective
compensatory response.
Finally, we find the downregulation of key genes like SHANK 2
and actin that are involved in the maintenance of the structural
and functional integrity of synapses.
Pathway analysis
Looking at pathways, we found a IPA-inferred pathway that is
related to [Ca2+]i homeostasis (Fig. 4A). The issue of [Ca
2+]i
dyshomeostasis is particularly relevant to AD. Recent findings
suggest that Ca2+ signaling is altered in AD long before the
appearance of macroscopic pathological changes [97,98]. [Ca2+]i
rises might affect formation of AbPP and Ab [99,100] and
promote accumulation of intraneuronal Ab [97]. Perturbation of
[Ca2+]i levels might also interfere with neurofibrillary tangle
formation [101,102]. An altered [Ca2+]i homeostasis in aging
neurons can have important functional consequences and impair
synaptic plasticity as well as learning or memory [102]. Some of
the genes, like CRAC and CASQ that we found changed by Ab-Al
can also promote [Ca2+]i deprivation. [Ca
2+]i deprivation can be
deleterious too as neurons depleted of Ca2+ can undergo death
and activate the apoptotic machinery [103,104].
The second pathway inferred by IPA indicates an overall
increase of glutamatergic neurotransmission which is intercon-
nected with the issue of [Ca2+]i dyshomeostasis. Glutamate
activates post-synaptic ionotropic receptors and promotes neuro-
toxic [Ca2+]i rises. Interestingly, we have previously shown that
Ab-Al elicits the formation of oligomers that selectively increase
NMDAR-mediated [Ca2+]i rises [8]. Excessive [Ca
2+]i rises trigger
robust oxidative stress, [101,105] and make neurons more
vulnerable to excitoxicity as free radicals inhibit glutamate re-
uptake [106]. Ab-Al can potentiate such loop, not only by
increasing NMDAR-evoked currents (as well as the expression of
NMDARs and AMPARs; [8]), but also by down regulating
glutamate transporters that mediate glutamate re-uptake. Thus,
glutamate and Ab-Al can operate synergistically to promote
excitotocic [Ca2+]i rises and oxidative stress and set the stage for a
self-perpetuating harmful loop. It must also be emphasized that
oxidative stress can enhance tau phosphorylation and tau-
dependent pathology which further exacerbates Ab-driven
pathology [97,107]. In conclusion, the changes in the gene
expression profile triggered by Ab-Al lend support to the idea that
this complex is largely involved in the molecular machinery that
regulates neuronal as well as synaptic dysfunction and loss
(summarized in Figure 6). Ab-Al seems to modulate the expression
of genes that are critical in controlling glutamatergic transmission,
Ca2+ homeostasis as we have previously shown [108], oxidative
stress, inflammation, and neuronal apoptosis. All these processes
are key steps in the development of AD pathology. Our analysis
can help to unravel the blueprint of the molecular determinants
that are set in motion by toxic exposures to the Ab-Al complex and
offer a new perspective on how Al can play a relevant role in AD
pathogenesis.
Matherials and Methods
Preparation of Ab-metal complexes
1.0 mg of synthetic Ab1–42 was dissolved to 1 mM in
hexafluorisopropanol (HFIP) for 40 min at room temperature.
After this incubation, the Ab1–42 solution was separated into
aliquots in microcentrifuge tubes. Hexafluorisopropanol was
removed under vacuum in a Speed Vac (Sc110 Savant
Instruments) and lyophilized peptide film was stored desiccated
at – 20uC. Immediately prior to use, the HFIP-treated aliquots
were completely re-suspended in distilled water to a concentration
of 50 mM (following a modified protocol from Dahlgren et al.,
2002). The Ab-Al complex was prepared with a 24 h dialysis
against a metal solution containing Al(C3H5O3)3 at T= 4uC
using Spectra/PorR Float-A-LyserR tubes (Spectrum Labs) with
1000 Molecular Weight Cut Offs (MWCO). The Ab-Al complex
was then dialysed against water (three water changes) for 24 h in
order to remove the excess of metal not bound to the peptide. The
same treatment was also performed with Ab alone. SH-SY5Y cells
were treated with Ab or Ab-Al complex at 0.5 mM peptide
concentration for 24 h. Aliquots of Ab and Ab–Al complex were
taken, after dialysis, at 48 h incubation time to be analyzed by
electron microscopy. Metal detection was done by atomic
absorption (electrothermal atomic absorption spectrometry or
flame atomic absorption spectrometry) and size exclusion
chromatography. After 48 h dialysis at 4uC, many short and
irregular protofibrillar structures were present in the Ab sample as
the consequence of self aggregation while few fibrils were
observed. By contrast, the Ab–Al complex was characterized by
a large population of small oligomeric aggregates that as previously
shown [8] possess marked neurotoxic effects. Thus, as previously
described [8]. Al freezes the oligomeric state of Ab.
Cell cultures
SH-SY5Y human neuroblastoma cells were purchased from
ECACC (European Collection of Cell Culture, Salisbury, UK).
SH-SY5Y human neuroblastoma cells were maintained in
Dulbecco’s modified Eagle’s medium (MEM): F-12 (1: 1) with L-
Glutamine and 15 mM Hepes (Gibco, Carlsbad, CA USA) at
37uC with 5% CO2 in a humidified atmosphere (90% humidity).
The medium was replaced every 2 days. Penicillin (100 units/ml;
Gibco, Carlsbad, CA USA) and streptomycin (100 mg/ml; Gibco,
Carlsbad, CA USA), 15% fetal bovine serum (FBS; Sigma Aldrich,
St. Louis, MO), and MEM non-essential amino acids (100x; Sigma
Aldrich, St. Louis, MO) were added to the medium. 0.25%
Trypsin-EDTA solution and phosphate buffered saline (PBS) were
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obtained from Sigma Aldrich (St. Louis, MO). SHSY5Y cells were
plated onto 6-well plates. The day after this plating, the culture
medium was replaced with the same medium with 2% FBS
containing Ab1–42 or Ab1–42-Al at 0.5 mM peptide concentration.
The cells were incubated with different Ab or Ab-Al for 24 h. The
cell treatment was also performed in the presence of metal (Al) at a
concentration 10-fold higher than the peptide concentration.
RNA isolation, quality control and labeling
Total RNA of neuroblastoma cells untreated or treated with
various Ab and Ab-Al was isolated using the Qiagen RNA/DNA
Mini Kit (Qiagen S.p.A., Milan, Italy) following the manufactur-
er’s instructions. 1 ml total RNA aliquots were used for quality
control by capillary electrophoresis using the RNA 6000 Nano
LabChip and the Agilent Bioanalyzer 2100 (Agilent Technologies,
Palo Alto, CA). All RNA samples used in this study showed no sign
of degradation. 1 mg of total RNA was amplified following the
SuperscriptTM Indirect RNA Amplification System Kit (Invitro-
genTM): total RNA was reverse transcribed into single-stranded
complementary DNA (cDNA) using oligo(dT) primer containing a
T7 promoter and Superscript III reverse transcriptase. RNase H
was then added together with E. coli DNA polymerase I and E. coli
DNA ligase, followed by a short incubation in order to achieve
synthesis of the second-strand cDNA. The purified double-strand
cDNA served as the template for the in vitro transcription reaction,
which was carried out overnight in the presence of T7-RNA
polymerase. This step generated antisense RNA (aRNA) molecules
complementary to the original mRNA targets, incorporating
amino-allyl UTP (aa-UTP) into the aRNA. 10 mg of purified
aRNA was coupled with Alexa Fluor 555 or Alexa Fluor 647 dyes
(Invitrogen, Grand Island, NY) according to the manufacturer
instructions.
Microarray
Labeled aRNA was dissolved in 90 ml of hybridization buffer,
denaturated at 90uC for 3 min and applied directly to human
OpArrays DNA microarray slides containing 35130 spotted
oligonucleotide sequences representing 29166 different human
genes (Operon Biotechnologies, Inc.). Each slide was hybridizated
with treated (either Ab, Ab-Al, or Al) and untreated (sham)
samples. Microarray hybridization was carried out in an
ArrayBooster Hybridization Station (Advalytix, Brunnthal, Ger-
many). The reaction was carried out overnight at 42uC.
Posthybridization washing was performed according to the
microarray slides manufacturer’s instructions. Two replicates of
each experiment were performed using different microarray slides,
Figure 6. Summary of genes, biological functions, and pathways associated with gene expression changes triggered by the
exposure to the Ab-Al complex in SH-SY5Y cells.
doi:10.1371/journal.pone.0015965.g006
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in which sample and control RNA, labeled either with Alexa Fluor
555 or Alexa Fluor 647 fluorochromes, were crossed in both
combinations (dye-swapping procedure). Each experiment used
material from the same cell culture and therefore represents a
technical replicate. The microarrays slides were scanned using a
GenePix 4000B laser scanner (Molecular Devices Corp., Sunny-
vale, CA, USA) and images were processed using Genepix 6.0
software.
Microarray data are deposited in the GEO public database
(accession number:GSE23000). All data are MIAME compliant.
Statistical analysis
Statistical analysis of the microarray data was performed using
Acuity 4.0 software (Molecular Devices Corp., Sunnyvale, CA,
USA). Initial results were normalized using Lowess algorithm and
filtered to exclude extreme outliers and flags. We also excluded
any spot that had no detectable response on all slides. The log-
ratios of expression were calculated as the base 2 logarithm of the
ratios of background-corrected intensity medians of red dye over
green dye intensities. In order to obtain a single expression value
for each gene, the internal replicates (1 to 14) were plotted versus
the technical replicates (6 for Ab treatment and 2 for Al and Ab-Al
complex treatment). The X-Y scatter plot confirmed that the data
were generally reproducible but we observed the presence of
extreme outlier values. Then we excluded the outliers and the
values of spots replicates within arrays were averaged using a
trimmed mean. We excluded any spot that had no detectable
response in all three treatments. Consequently, the final dataset
was composed of 28676 genes. In order to identify important
genes with great statistical confidence, statistical testing and fold
change criteria were employed simultaneously. A gene was
considered to be differentially expressed if it had an absolute
value of a log-ratio higher or equal to 0.5, representing a fold-
change of 1.4 in transcript quantity. Student’s t-test was applied
and statistical significance set at p,0.05.
TaqMan real-time quantitative PCR (qRT-PCR)
A qRT-PCR analysis was performed on SH-SY5Y neuroblas-
toma treated with Ab, Ab-Al complex or Al alone to verify the
gene expression profile of APLP1, APLP2, MAPT and AbPP, the
genes we identified by microarray analysis. Real time quantitative
PCR was carried out in a total volume of 25 ml containing 1X
TaqMan Universal PCR Master mix, no AmpErase UNG and
2.5 ml of cDNA using the TaqMan assay (TAB) on ABI 7300
Sequence Detection System (ABI, Foster City, CA). Gene-specific
primers and probe sets for each gene (APLP1; Hs00193069-M1)
(APLP2; Hs00155778-M1) (AbPP; Hs00169098-M1) (MAPT;
Hs00213491-M1) (GAPDH; Hs99999905-m1) were obtained
from Assay-on-Demand Gene Expression Products (Applied
Biosystems). Duplicate samples were run for each gene along with
a no-template control. The housekeeping gene GAPDH was used
as an internal control to normalize the expression of target genes.
The real time amplifications included 10 minutes at 95uC
(AmpliTaq Gold activation), followed by 40 temperature cycles
for 15 seconds at 95uC and for 1 minute at 60uC. Relative
expression levels were calculated for each sample after normali-
zation against the housekeeping gene GAPDH, using the DDCt
method for comparing relative fold expression differences [109].
Supporting Information
Figure S1 Graph bars show mRNA levels of APLP1 (a)
and APLP2 (b) as measured by real-time PCR in SH-
SY5Y cell exposed to the Ab-Al complex, Ab, or Al
(*indicates p,0.0001 vs control; # indicates p,0.0001
vs Ab and Al, n=3). Values are expressed as means 6S.E.M.
(TIF)
Figure S2 Graph bars show mRNA levels of AbPP (a)
and MAPT (b) as measured by real-time PCR in SH-
SY5Y cell exposed to the Ab-Al complex, Ab, or Al
(*indicates p,0.0001 vs control, # indicates p,0.0001
vs Ab and Al, n=3). Values are expressed as means 6S.E.M.
(TIF)
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upon exposure to Ab-Al compared to exposures to Ab or
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(DOC)
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(DOC)
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(DOC)
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